title: Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors.
abstract: Targeting multiple components of the MAPK pathway can prolong the survival of patients with BRAFV600E melanoma. This approach is not curative, as some BRAF-mutated melanoma cells are intrinsically resistant to MAPK inhibitors (MAPKi). At the systemic level, our knowledge of how signaling pathways underlie drug resistance needs to be further expanded. Here, we have shown that intrinsically resistant BRAF-mutated melanoma cells with a low basal level of mitochondrial biogenesis depend on this process to survive MAPKi. Intrinsically resistant cells exploited an integrated stress response, exhibited an increase in mitochondrial DNA content, and required oxidative phosphorylation to meet their bioenergetic needs. We determined that intrinsically resistant cells rely on the genes encoding TFAM, which controls mitochondrial genome replication and transcription, and TRAP1, which regulates mitochondrial protein folding. Therefore, we targeted mitochondrial biogenesis with a mitochondrium-targeted, small-molecule HSP90 inhibitor (Gamitrinib), which eradicated intrinsically resistant cells and augmented the efficacy of MAPKi by inducing mitochondrial dysfunction and inhibiting tumor bioenergetics. A subset of tumor biopsies from patients with disease progression despite MAPKi treatment showed increased mitochondrial biogenesis and tumor bioenergetics. A subset of acquired drug-resistant melanoma cell lines was sensitive to Gamitrinib. Our study establishes mitochondrial biogenesis, coupled with aberrant tumor bioenergetics, as a potential therapy escape mechanism and paves the way for a rationale-based combinatorial strategy to improve the efficacy of MAPKi.
authors.forename: Gao
authors.initials: G
authors.lastname: Zhang
authors.forename: Dennie T
authors.initials: DT
authors.lastname: Frederick
authors.forename: Lawrence
authors.initials: L
authors.lastname: Wu
authors.forename: Zhi
authors.initials: Z
authors.lastname: Wei
authors.forename: Clemens
authors.initials: C
authors.lastname: Krepler
authors.forename: Satish
authors.initials: S
authors.lastname: Srinivasan
authors.forename: Young Chan
authors.initials: YC
authors.lastname: Chae
authors.forename: Xiaowei
authors.initials: X
authors.lastname: Xu
authors.forename: Harry
authors.initials: H
authors.lastname: Choi
authors.forename: Elaida
authors.initials: E
authors.lastname: Dimwamwa
authors.forename: Omotayo
authors.initials: O
authors.lastname: Ope
authors.forename: Batool
authors.initials: B
authors.lastname: Shannan
authors.forename: Devraj
authors.initials: D
authors.lastname: Basu
authors.forename: Dongmei
authors.initials: D
authors.lastname: Zhang
authors.forename: Manti
authors.initials: M
authors.lastname: Guha
authors.forename: Min
authors.initials: M
authors.lastname: Xiao
authors.forename: Sergio
authors.initials: S
authors.lastname: Randell
authors.forename: Katrin
authors.initials: K
authors.lastname: Sproesser
authors.forename: Wei
authors.initials: W
authors.lastname: Xu
authors.forename: Jephrey
authors.initials: J
authors.lastname: Liu
authors.forename: Giorgos C
authors.initials: GC
authors.lastname: Karakousis
authors.forename: Lynn M
authors.initials: LM
authors.lastname: Schuchter
authors.forename: Tara C
authors.initials: TC
authors.lastname: Gangadhar
authors.forename: Ravi K
authors.initials: RK
authors.lastname: Amaravadi
authors.forename: Mengnan
authors.initials: M
authors.lastname: Gu
authors.forename: Caiyue
authors.initials: C
authors.lastname: Xu
authors.forename: Abheek
authors.initials: A
authors.lastname: Ghosh
authors.forename: Weiting
authors.initials: W
authors.lastname: Xu
authors.forename: Tian
authors.initials: T
authors.lastname: Tian
authors.forename: Jie
authors.initials: J
authors.lastname: Zhang
authors.forename: Shijie
authors.initials: S
authors.lastname: Zha
authors.forename: Qin
authors.initials: Q
authors.lastname: Liu
authors.forename: Patricia
authors.initials: P
authors.lastname: Brafford
authors.forename: Ashani
authors.initials: A
authors.lastname: Weeraratna
authors.forename: Michael A
authors.initials: MA
authors.lastname: Davies
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Wargo
authors.forename: Narayan G
authors.initials: NG
authors.lastname: Avadhani
authors.forename: Yiling
authors.initials: Y
authors.lastname: Lu
authors.forename: Gordon B
authors.initials: GB
authors.lastname: Mills
authors.forename: Dario C
authors.initials: DC
authors.lastname: Altieri
authors.forename: Keith T
authors.initials: KT
authors.lastname: Flaherty
authors.forename: Meenhard
authors.initials: M
authors.lastname: Herlyn
mesh_terms: D000818:Animals; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism; D048049:Extracellular Signal-Regulated MAP Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D005260:Female; D006146:Guanidines / Q000494:pharmacology*; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D006801:Humans; D047029:Lactams, Macrocyclic / Q000494:pharmacology*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008928:Mitochondria / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D063154:Mitochondrial Dynamics / Q000187:drug effects*; D024101:Mitochondrial Proteins / Q000235:genetics / Q000378:metabolism; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism
chemical_list: D004268:DNA-Binding Proteins; D006146:Guanidines; D018841:HSP90 Heat-Shock Proteins; D047029:Lactams, Macrocyclic; D024101:Mitochondrial Proteins; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors; C499631:TFAM protein, human; C092306:TRAP1 protein, human; D014157:Transcription Factors; C557898:gamitrinib-G4; D048049:Extracellular Signal-Regulated MAP Kinases